Secondary Stroke Prevention After Ischemic Stroke in Patients with Alzheimer's Disease and Other Dementia Disorders
(2020) In Journal of Alzheimer's disease : JAD 73(3). p.1013-1021- Abstract
BACKGROUND: Recurrent ischemic stroke (IS) increases the risk of cognitive decline. To lower the risk of recurrent IS, secondary prevention is essential. OBJECTIVE: Our aim was to compare post-discharge secondary IS prevention and its maintenance up to 3 years after first IS in patients with and without Alzheimer's disease and other dementia disorders. METHODS: Prospective open-cohort study 2007-2014 from the Swedish national dementia registry (SveDem) and the Swedish national stroke registry (Riksstroke). Patients with dementia who experienced an IS (n = 1410; 332 [23.5%] with Alzheimer's disease) were compared with matched non-dementia IS patients (n = 7150). We analyzed antiplatelet, anticoagulant, blood pressure lowering, and statin... (More)
BACKGROUND: Recurrent ischemic stroke (IS) increases the risk of cognitive decline. To lower the risk of recurrent IS, secondary prevention is essential. OBJECTIVE: Our aim was to compare post-discharge secondary IS prevention and its maintenance up to 3 years after first IS in patients with and without Alzheimer's disease and other dementia disorders. METHODS: Prospective open-cohort study 2007-2014 from the Swedish national dementia registry (SveDem) and the Swedish national stroke registry (Riksstroke). Patients with dementia who experienced an IS (n = 1410; 332 [23.5%] with Alzheimer's disease) were compared with matched non-dementia IS patients (n = 7150). We analyzed antiplatelet, anticoagulant, blood pressure lowering, and statin treatment as planned medication initiation at discharge and actual dispensation of medications at first, second, and third year post-stroke. RESULTS: At discharge, planned initiation of medication was higher in patients with dementia compared to non-dementia patients for antiplatelets (OR with 95% CI for fully adjusted models 1.23 [1.02-1.48]) and lower for blood pressure lowering medication (BPLM; 0.57 [0.49-0.67]), statins (0.57 [0.50-0.66]), and anticoagulants (in patients with atrial fibrillation - AF; 0.41 [0.32-0.53]). When analysis for antiplatelets was stratified according to the presence of AF, ORs for receiving antiplatelets remained significant only in the presence of AF (in the presence of AF 1.56 [1.21-2.01], in patients without AF 0.99 [0.75-1.33]). Similar trends were observed in 1st, 2nd, and 3rd year post-stroke. CONCLUSIONS: Dementia was a predictor of lower statin and BPLM use. Patients with dementia and AF were more likely to be prescribed antiplatelets and less likely to receive anticoagulants.
(Less)
- author
- Zupanic, Eva ; Kramberger, Milica G. ; von Euler, Mia ; Norrving, Bo LU ; Winblad, Bengt ; Secnik, Juraj ; Fastbom, Johan ; Eriksdotter, Maria and Garcia-Ptacek, Sara
- organization
- publishing date
- 2020-02-04
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer’s disease, anticoagulants, antihypertensive agents, cohort studies, dementia, hydroxymethylglutaryl-CoA reductase inhibitors, ischemic stroke, platelet aggregation inhibitors, secondary prevention
- in
- Journal of Alzheimer's disease : JAD
- volume
- 73
- issue
- 3
- pages
- 9 pages
- publisher
- IOS Press
- external identifiers
-
- pmid:31884483
- scopus:85079204467
- ISSN
- 1387-2877
- DOI
- 10.3233/JAD-191011
- language
- English
- LU publication?
- yes
- id
- f159b7dd-bc6b-4fb1-a6d2-48c055b0e716
- date added to LUP
- 2020-02-21 14:30:14
- date last changed
- 2024-02-16 11:34:46
@article{f159b7dd-bc6b-4fb1-a6d2-48c055b0e716, abstract = {{<p>BACKGROUND: Recurrent ischemic stroke (IS) increases the risk of cognitive decline. To lower the risk of recurrent IS, secondary prevention is essential. OBJECTIVE: Our aim was to compare post-discharge secondary IS prevention and its maintenance up to 3 years after first IS in patients with and without Alzheimer's disease and other dementia disorders. METHODS: Prospective open-cohort study 2007-2014 from the Swedish national dementia registry (SveDem) and the Swedish national stroke registry (Riksstroke). Patients with dementia who experienced an IS (n = 1410; 332 [23.5%] with Alzheimer's disease) were compared with matched non-dementia IS patients (n = 7150). We analyzed antiplatelet, anticoagulant, blood pressure lowering, and statin treatment as planned medication initiation at discharge and actual dispensation of medications at first, second, and third year post-stroke. RESULTS: At discharge, planned initiation of medication was higher in patients with dementia compared to non-dementia patients for antiplatelets (OR with 95% CI for fully adjusted models 1.23 [1.02-1.48]) and lower for blood pressure lowering medication (BPLM; 0.57 [0.49-0.67]), statins (0.57 [0.50-0.66]), and anticoagulants (in patients with atrial fibrillation - AF; 0.41 [0.32-0.53]). When analysis for antiplatelets was stratified according to the presence of AF, ORs for receiving antiplatelets remained significant only in the presence of AF (in the presence of AF 1.56 [1.21-2.01], in patients without AF 0.99 [0.75-1.33]). Similar trends were observed in 1st, 2nd, and 3rd year post-stroke. CONCLUSIONS: Dementia was a predictor of lower statin and BPLM use. Patients with dementia and AF were more likely to be prescribed antiplatelets and less likely to receive anticoagulants.</p>}}, author = {{Zupanic, Eva and Kramberger, Milica G. and von Euler, Mia and Norrving, Bo and Winblad, Bengt and Secnik, Juraj and Fastbom, Johan and Eriksdotter, Maria and Garcia-Ptacek, Sara}}, issn = {{1387-2877}}, keywords = {{Alzheimer’s disease; anticoagulants; antihypertensive agents; cohort studies; dementia; hydroxymethylglutaryl-CoA reductase inhibitors; ischemic stroke; platelet aggregation inhibitors; secondary prevention}}, language = {{eng}}, month = {{02}}, number = {{3}}, pages = {{1013--1021}}, publisher = {{IOS Press}}, series = {{Journal of Alzheimer's disease : JAD}}, title = {{Secondary Stroke Prevention After Ischemic Stroke in Patients with Alzheimer's Disease and Other Dementia Disorders}}, url = {{http://dx.doi.org/10.3233/JAD-191011}}, doi = {{10.3233/JAD-191011}}, volume = {{73}}, year = {{2020}}, }